A guide for travel vaccines - compiled by Jane Chiodini

Always use this table in conjunction with information from the SmPC at www.medicines.org.uk the BNF at www.medicines.org.uk the SNF at www.medicines.org.uk the www.medicines.org.uk the www.medicines

VACCINE NAME		AGE GROUPS	WHEN TO BOOST- general principles and comments	
HEPATITIS A vaccine (and schedules)				
Hep A vaccine SmPCs	have different timings - note	Ideally, follow the summary of product		
VAQTA® Paediatric	2 dose schedule of	1-17 years	characteristics but in late - presenting	
VAQTA® Adult	hepatitis. A vaccine should be given at day 0 and then 6 to 12 months after the initial dose as recommended in Green Book for hep A vaccines.	18 years and over	travellers, a course does not need to be restarted. Protection is expected for 25 years from the second dose, then a further booster is generally not needed, except for those at ongoing	
Avaxim®		16 years and over		
Avaxim® Junior		1-15 years		
Havrix Junior		1-15 years		
Monodose®		•		
Havrix Monodose®	Regimes may vary in	16 years and over	risk (<u>UKHSA 2024</u>). Also see NaTHNaC & info on Hepatitis A ** plus detail	
	SmPCs, see above • & key		below within the ' Key ' section regarding	
	·		GSK 'Havrix' vaccines***.	
TYPHOID vaccine			- CON THAT IN TACONICS	
Typhim Vi® Single dos	se	2 years and over	3 years	
		(but see GB for off-		
Vivotif® (Ty21a) Oral vaccine (LIVE)		license use from 12mths)	3 years (Take with cold or luke warm drink 1	
Taken on days 0, 2 &		5 years and over	hr before meal, swallow capsule whole)	
HEPATITIS B vaccine (and schedules) Important – Hep B now in the childhood programme not included her				
Engerix B [®] - 0, 1 and 6 months		Over 16 years	Note: 0, 1, 2 month schedule - Green Book	
Engerix B ® - 0, 1, 2 an	nd 12 months	Over 16 years	now advises a 4 th dose at 12 months in the 2024 edition, see Ch.18 pages 16/17.	
Engerix B [®] - 0, 7, 21 o	days & 12 months	Over 18 years in SmPC –		
		But also 16 -18 years in Green Book	Green Book policy for hepatitis B for all who	
Engerix B® Paediatric 0, 1, 6 months		0 to 15 years	have received a primary course (which	
Engerix B® Paediatric 0, 1, 2 and 12 months		0 to 15 years	would include travellers) also children	
Engerix B® Option of two doses of 1 ml (20mcg)		11 – 15 years	vaccinated according to the routine childhood schedule and individuals at high	
for low-compliance adolescents given 6 months		•	risk of exposure do not require a reinforcing	
apart when the risk of hepatitis B is low and			dose of hep B containing vaccine. This	
completion of course can be assured before risk			advice now includes healthcare workers	
is high			(certain groups not included i.e. people with	
HBvaxPRO® 0, 1, and 6 months		16 years and over	kidney failure, at the time of a significant	
HBvaxPRO ® 0, 1, 2 and 12 months		16 years and over	exposure & healthcare and laboratory	
HBvaxPRO [®] Paediatric 0, 1 & 6 months		0 – 15 years	workers who have not responded to the	
HBvaxPRO Paediatric	0, 1, 2 and 12 months	0 – 15 years	primary course). Read Ch. 18, page 17 in GB	
Heplisav B® ▼ 0 and 1	month	18 years and over	Heplislav B may be preferable in those likely	
			to have a poorer response – see page 16/17	
			in the <u>Green Book</u> and be sure to read all the detail on this newer vaccine.	
COMBINED vaccine	es (and schedules)		the detail on this newer vaccine.	
Twinrix Adult® (Hepatitis A and B) 0, 1, 6 months		16 years and over	See information about hepatitis A and hepatitis B regarding boosters above. Twinrix Adult rapid schedule could be given from 16 yrs where rapid protection required – see GB page 16, but also national PGD from UKHSA	
Twinrix Adult® 0, 7, 21, days and 12 months		18 years and over		
Twinrix Paediatric® 0, 1, 6 months		1 – 15 years		
	Ambirix® (Hepatitis A and B) 0 & 6-12 months			
Discontinued combined Hep A & Typhoid – important to be aware of incase these vaccines are documented in records. These were Hepatyrix and VIATIM® used only for adults. Both contained an adult dose of hepatitis A and a dose of typhoid.				
Tetanus, polio & low dose diphtheria (for travel purposes)				
-	k at destination and UK	From 6 years - for	10 years if risk at destination and risk of	
	nore than 10 years ago –	travel purposes expect	immunoglobulin not being available	
see Green Book p372	s than 10 years ago	to give older than this	arrangiasami nac senig available	
35 8.15 5.25				

VACCINE NAME	AGE GROUPS	WHEN TO BOOST - general principles and comments		
MENINGOCOCCAL vaccine				
Menveo® Single dose (conjugate vaccine)	2 years	5-yearly for Hajj, Umrah certificate purposes as		
Nimenrix Single dose (conjugate vaccine) MenQuadfi Single dose (conjugate vaccine)	6 weeks of age	per KSA in 2017 ⁺ For travel, boost every 5 yrs until more data available. See NaTHNaC at reinforcing immunisation https://goo.gl/6eSWmu N.B. Children under 1 year need different dosing –		
meniquan enigle uses (conjugate russine)	age and older	see Green Book and NaTHNaC & note SmPC differs		
RABIES vaccine 2.5IU; one vial (and schedules)				
Rabipur® 0, 7, 21 or 28 days Accelerated primary course given IM on days 0, 3, 7 and 365 when there is insufficient time to complete the 0, 7, 21-28 day course. Important to note: Rabies Vaccine BP made by Sanofi Pasteur was discontinued in 2022. Verorab® is now licensed in the UK, but is not in the Green Book as yet, so for now see news item on TravelHealthPro here	Any age but careful risk assessment under 1 year	Many travellers may not need a booster but one single booster dose of vaccine can be considered following thorough risk assessment, in those who completed a primary course over a year ago. This may be most effective if offered 5 years of more after the primary course if travel is assessed as high risk. See Vaccine Update page 5 in issue 282.		
YELLOW FEVER vaccine				
Stamaril® Single dose (LIVE)	Over 9 months	Lifelong in most. See resources for latest details. Certificate valid 10 days post vaccination		
CHOLERA vaccine	1			
Important: the Green Book states 'the two vaccines instructions, healthcare professionals must check policy Dukoral® Oral vaccine. 2 doses, minimum 1 wk. and maximum 6 weeks apart, given to those from 6yrs of age. 3 doses given in those 2 – 6 yrs old. If more than 6 weeks have elapsed between doses, the primary immunisation course should be restarted.	2 years and over for both vaccines. Note: children 2 – 6 years, the buffer solution			
Vaxchora® Oral vaccine (LIVE) Single dose	volume is reduced and amount is different between products	NBM 1 hr before & after vaccine No data available on booster interval. Contraindicated for immunosuppressed individuals. Advise careful handwashing after visiting the toilet and preparing food for at least 14 days after taking the vaccine		
JAPANESE ENCEPHALITIS vaccine				
IXIARO® 0 and 28 days for all age groups. 0.5ml dose for adults & 3 yr to < 18 yr age group 0.25ml for 2 months to < 3yr age group (See SPC for specific instructions) Note: SPC & GB change for new 0 & 7 days schedule in 18-64 yrs & off license in children from 2 months and over 65 yrs when genuinely no time to complete standard schedule	From 2 months	1 year if at continuous/further risk All others, boost at 12-24 months but see GB for those 65 years and older. Second booster in 18-64 years offer at 10 years. Please see GB for children and those over 65 years for more specific information. Note: primary immunisation should ideally be completed at least one wk prior to JEV exposure		
TICK BORNE ENCEPHALITIS vaccine				
Tico-Vac® 3 doses of 0.5ml on day 0, 1-3 months after 1 st dose, 5-12 months after 2 nd dose For rapid short-term protection – 2 nd dose can be given 2 weeks after 1 st dose – see 'Green Book'	16 years and over	Booster at 3 years after initial 3 dose course is completed if individual continues to be at risk. After this, boosters can be given every 5 years but in those aged > 60 years, booster intervals should not exceed three years		
Tico-Vac® Junior (0.25ml) 3 doses – same dosing schedule as adult Tico-Vac®	1 year to below 16 years of age			

DENGUE vaccine

Qdenga® ▼ (LIVE)

Use in those 4 years and above. Two doses of 0.5mL on a 0 and 3 months schedule.

Note: Qdenga should be administered by subcutaneous injection, preferably in the upper arm in the region of the deltoid. There are currently no data available on co-administration with other live vaccines such as MMR.

From 4 years

The need for a booster has not been established.

Of importance: In the UK, according to guidance in the Green Book, Qdenga® vaccine is currently recommended only for those with previous dengue infection. See Chapter 15a, page 4 on 'Determining previous infection'. This is very important to read, including information that says 'Where there is any uncertainty about the previous history, the potential risk of vaccination should be clearly explained'. Figure 1 on page 6 is a useful tool to use and Table 1 illustrates consideration of eligibility for vaccination.

KEY

- + KSA = Kingdom of Saudi Arabia guidance, see NaTHNaC Hajj and Umrah (travelhealthpro.org.uk)
- * Within the Summary of Product Characteristics (SmPC)
- *** The Green Book Ch. 17 Hepatitis A (2024) refers to all hepatitis A products, so the 25 year protection also applies to the combined products and paediatric hepatitis A vaccines. Until further evidence is available on persistence of protective immunity, a further booster at 25 years is generally not needed except for those at ongoing risk. See the Green Book chapter (page 9) and NaTHNaC document at https://travelhealthpro.org.uk/factsheet/21/hepatitis-a***SmPCs for GSK vaccines Havrix Monodose & Havrix Junior Monodose (2022) and Avaxim Junior (2023) states 'Current data do not support the need for further booster vaccination among immune-competent subjects after 2 dose vaccination course' but we continue to follow UKHSA guidance as previously described, even in this situation.

▼Black triangle scheme - drug subject to additional monitoring - see here

From August 2024,

- LIVE vaccines were indicated on this chart. For further information regarding types of vaccines see Types of vaccine | Vaccine Knowledge Project (ox.ac.uk)
- When it comes to the need to give more than one live travel vaccine make sure you are aware of the guidance
 within the individual disease chapters and also <u>Contraindications and special considerations</u>: the green book,
 <u>chapter 6 GOV.UK (www.gov.uk)</u> to ensure you have the correct timing intervals

Sources of Information for this chart taken from:

- UK Health Security Agency (2021) Immunisation Against Infectious Diseases The Green Book with subsequent updates and revised chapters found on this website. <u>Immunisation against infectious disease - GOV.UK</u> (www.gov.uk)
- Green Book 'travel only' chapters also found on TravelHealthPro at <u>NaTHNaC The green book travel chapters</u> (travelhealthpro.org.uk)
- Electronic Medicines Compendium <u>www.medicines.org.uk/emc/</u>
- National websites www.travelhealthpro.org.uk and www.travax.nhs.uk

IMPORTANT – Where there is a difference between the Green Book and the SmPC, the Green Book should followed – see first paragraph of <u>Immunisation procedures: the green book, chapter 4 - GOV.UK (www.gov.uk)</u>

This chart was designed & created by Jane Chiodini © www.janechiodini.co.uk Updated 15.11.24